中國同輻(01763.HK):中核安科鋭再次獲得19台高端放射治療類設備配置證
格隆匯3月18日丨中國同輻(01763.HK)公吿,近日,國家衞生健康委員會發布了2024年甲類大型醫用設備准予許可名單,其中,高端放射治療類設備共發放配置證28台,中國同輻附屬公司中核安科鋭(天津)醫療科技有限責任公司X-射線立體定向放射外科治療系統(含CyberKnife)(射波刀)獲得19台,佔比68%。
射波刀為腫瘤治療設備,同時深度融合人工智能和大數據模型驅動,能夠實現髮絲級別的重複精度,基於AI的實時追蹤技術能夠同步跟隨腫瘤位置變化,為腫瘤患者提供更精準、安全、高效的放射治療服務。
由於大型醫用設備使用技術複雜、資金投入量大、運行成本高、對醫療費用影響大,國家對大型醫用設備採取配置實施許可准入制度。2023年國家衞生健康委員會發布的「十四五」大型醫用設備配置規劃中,甲類高端放射治療類設備計劃發佈配置證76台,截至目前已發佈45台,其中,中核安科鋭射波刀共獲得配置證28台,佔比62%。
本次射波刀配置證獲得後,中國同輻在高端放療設備的市場份額將進一步擴大,充分彰顯了行業與客户的高度認可,預計隨着後續的設備銷售,將對中國同輻的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.